Clinical Trials Browser

Phase 2 × Interventional × Rosiglitazone × Clear all

NCT04114136 2026-04-24

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

Phase 2 Recruiting

DermatologicGastrointestinalHead & Neck

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hepatocellular, Melanoma

NCT00004180 2023-06-26

Rosiglitazone in Treating Patients With Liposarcoma

Phase 2 Completed

Liposarcoma, Sarcoma

NCT00616642 2020-08-14

Rosiglitazone in Treating Patients With Pituitary Tumors

Phase 2 Terminated

1 enrolled 4 charts

Pituitary Neoplasms, Central Nervous System Neoplasms

NCT00612066 2020-08-06

Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)

Phase 2 Terminated

2 enrolled 5 charts

Pituitary ACTH Hypersecretion

NCT00178841 2016-02-17

Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL

Phase 2 Completed

4 enrolled 5 charts

DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT00098852 2014-01-06

Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer

Phase 2 Unknown

EndocrineHead & Neck

Thyroid Cancer, Papillary, Head and Neck Neoplasms, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT00369174 2013-02-13

Rosiglitazone Maleate in Treating Patients With Oral Leukoplakia

Phase 2 Completed

Leukoplakia, Oral